NEOPROL
Intravenous Induction and Maintenance of Anesthesia
Company Overview
Snapshot
Founded in August 2014, NEOPROL operates with 1-10 employees. The company has secured funding across one round from one investor. In March 2019, NEOPROL received its seed funding from Integra Holdings.
Business overview
NEOPROL is a Health Tech & Life Sciences company focused on developing advanced formulations for anesthesia drugs. Its core product, NP-09, is an improved, novel bioequivalent of propofol, demonstrating superiority over existing alternatives like Diprivan. The company operates within the Pharmaceuticals sector, specifically in Drugs Discovery & Development, leveraging nanotechnology in its research and development efforts. NEOPROL targets the global healthcare market, serving providers within the life sciences and pharmaceuticals industries.
Log in to access full profile ›Company Intelligence Q&A
- What is NEOPROL's primary focus?
- NEOPROL develops new formulations for anesthesia drugs, with a primary focus on improving existing solutions like propofol.
- What is the key product developed by NEOPROL?
- NEOPROL's key product is NP-09, an advanced preclinical development of an improved formulation and novel bioequivalent of propofol.
- When was NEOPROL founded?
- NEOPROL was founded in August 2014.
- Which investor participated in NEOPROL's funding round?
- In March 2019, Integra Holdings participated in NEOPROL's seed funding round.
- What is the current development stage of NEOPROL's product?
- NEOPROL's NP-09 is currently in advanced preclinical development, demonstrating superiority over existing alternatives like Diprivan.